<a href="https://www.fiercebiotech.com/biotech/ada-astrazenecas-oral-glp-1-shows-competitive-efficacy-standard-tolerability-phase-2" hreflang="en">ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program</a>
AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, has shown promising results in phase 2 trials for weight loss and glycemic control in patients with obesity and Type 2 diabetes, surpassing expectations and positioning the company for significant future revenue in obesity treatments. The company plans to advance elecoglipron into phase 3 studies and explore its use in combination therapies.
AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, has demonstrated competitive efficacy in phase 2 trials for obesity and Type 2 diabetes, with promising weight loss and glycemic control results surpassing other oral GLP-1 agents. This positions AZ well for significant market penetration and potential revenue growth in the burgeoning obesity treatment space, especially as they proceed to phase 3 trials and explore combination therapies with their SGLT2 inhibitor, Farxiga.